CARLSBAD, CA - Palisade Bio, Inc. (NASDAQ: PALI), a biopharmaceutical company, has reported progress in its strategic collaboration with bioinformatics specialist Strand Life Sciences, aimed at advancing precision medicine for ulcerative colitis (UC). The partnership has identified potential PDE4-related biomarkers that could lead to more targeted treatments for UC.
The company's research, which integrates clinical biomarkers, disease activity measures, and transcriptomics data, is focused on refining patient selection strategies to optimize clinical outcomes. Dr. Mitch Jones, CMO at Palisade Bio, emphasized the company's commitment to developing precision medicine solutions for UC and other inflammatory diseases.
JD (NASDAQ:JD) Finley, CEO of Palisade Bio, expressed the company's aim to become a leader in precision medicine within inflammatory and fibrotic indications. Palisade Bio's efforts are part of a broader initiative to tailor personalized therapies for patients with UC, potentially improving the effectiveness of PDE4-inhibitor treatments.
Palisade Bio's work in this area is ongoing, and the company continues to seek innovative approaches to enhance the treatment landscape for UC. This update is based on a press release statement from Palisade Bio.
In other recent news, Palisade Bio has made significant strides in the development of its ulcerative colitis (UC) treatment, PALI-2108. The biopharmaceutical company recently secured a Canadian patent for the drug and plans to initiate a Phase 1 clinical study by the end of 2024. Ladenburg Thalmann has maintained a Buy rating for Palisade Bio, citing the promising potential of PALI-2108 to offer improved clinical remission rates.
In addition to these developments, Palisade Bio has also announced the appointment of Margery Fischbein to its Board of Directors. Her extensive experience in healthcare investment banking and executive roles in the biotechnology industry is expected to support the company's strategic objectives.
Moreover, Palisade Bio has secured approximately $4 million in a private placement agreement with an institutional investor, with plans to allocate the net proceeds for working capital and general corporate purposes. These recent developments provide a snapshot of Palisade Bio's ongoing efforts in the biopharmaceutical space.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.